Logo Logo
Help
Contact
Switch language to German
Der Einfluss verschiedener Strategien der antiresorptiven Therapie auf den Zeitpunkt des Auftretens und den chirurgischen Therapieerfolg der Medikamenten-assoziierten Kiefernekrose
Der Einfluss verschiedener Strategien der antiresorptiven Therapie auf den Zeitpunkt des Auftretens und den chirurgischen Therapieerfolg der Medikamenten-assoziierten Kiefernekrose
Objectives: Few data exist focusing on differences in the time to disease onset and the success rates in patients suffering from medication-related osteonecrosis of the jaw (MRONJ) dependent on their different antiresorptive treatment. The purpose of this study was to analyse and compare these variables for patients treated with bisphosphonates (BP) or denosumab (DNO), and for patients who switched the antiresorptive drug (BP/DNO). Patients and Methods: A retrospective single-center cohort study with patients suffering from MRONJ was conducted. The predictor variable was the antiresorptive treatment, the outcome variables were I) time to onset of MRONJ (defined as time of antiresorptive treatment to MRONJ diagnosis) and II) treatment success (defined as mucosal integrity 12 months postoperatively). The other variables include data on demographic, underlying disease, MRONJ stage, and trigger events. Cox- and logistic-regression, and Kruskal-Wallis test were applied. Results: One hundred thirty two patients were included and divided into three groups: group I (BP) n=45 patients, n=59 lesions; group II (BP/DNO) n=42 patients, n=71 lesions; group III (DNO) n=45 patients, n=62 MRONJ lesions. Treatment success and time to onset differed significantly between the groups: success rates in group I (84.7%) were significantly lower than in group II (91.5%, (p<.0001), and group III (90.3%, p<.005). The onset was significantly earlier in group III DNO (median 2.0 years, Q0.25: 1.49, Q0.75: 2.98; CI95: 1.93 – 2.83) compared with group II BP/DNO (median 4.07 years, Q0.25: 1.64, Q0.75: 6.70; CI95: 3.55 – 5.68) and group I BP (median 3.86 years, Q0.25: 1.69, Q0.75: 6.46; CI95: 3.43 – 5.87). Conclusion: The different antiresorptive drugs show distinctive characteristics of time to onset and treatment success with the lowest success rates in the bisphosphonates group and the earliest onset in the denosumab group. The switch of the antiresorptive therapy (bisphosphonate to denosumab) did not influence the outcome variables negatively.
MRONJ, Therapieerfolg, Zeitlicher Verlauf, drug holiday, Bisphosphonate, Denosumab, ONJ
Wick, Alexander
2021
German
Universitätsbibliothek der Ludwig-Maximilians-Universität München
Wick, Alexander (2021): Der Einfluss verschiedener Strategien der antiresorptiven Therapie auf den Zeitpunkt des Auftretens und den chirurgischen Therapieerfolg der Medikamenten-assoziierten Kiefernekrose. Dissertation, LMU München: Faculty of Medicine
[img]
Preview
PDF
Wick_Alexander.pdf

3MB

Abstract

Objectives: Few data exist focusing on differences in the time to disease onset and the success rates in patients suffering from medication-related osteonecrosis of the jaw (MRONJ) dependent on their different antiresorptive treatment. The purpose of this study was to analyse and compare these variables for patients treated with bisphosphonates (BP) or denosumab (DNO), and for patients who switched the antiresorptive drug (BP/DNO). Patients and Methods: A retrospective single-center cohort study with patients suffering from MRONJ was conducted. The predictor variable was the antiresorptive treatment, the outcome variables were I) time to onset of MRONJ (defined as time of antiresorptive treatment to MRONJ diagnosis) and II) treatment success (defined as mucosal integrity 12 months postoperatively). The other variables include data on demographic, underlying disease, MRONJ stage, and trigger events. Cox- and logistic-regression, and Kruskal-Wallis test were applied. Results: One hundred thirty two patients were included and divided into three groups: group I (BP) n=45 patients, n=59 lesions; group II (BP/DNO) n=42 patients, n=71 lesions; group III (DNO) n=45 patients, n=62 MRONJ lesions. Treatment success and time to onset differed significantly between the groups: success rates in group I (84.7%) were significantly lower than in group II (91.5%, (p<.0001), and group III (90.3%, p<.005). The onset was significantly earlier in group III DNO (median 2.0 years, Q0.25: 1.49, Q0.75: 2.98; CI95: 1.93 – 2.83) compared with group II BP/DNO (median 4.07 years, Q0.25: 1.64, Q0.75: 6.70; CI95: 3.55 – 5.68) and group I BP (median 3.86 years, Q0.25: 1.69, Q0.75: 6.46; CI95: 3.43 – 5.87). Conclusion: The different antiresorptive drugs show distinctive characteristics of time to onset and treatment success with the lowest success rates in the bisphosphonates group and the earliest onset in the denosumab group. The switch of the antiresorptive therapy (bisphosphonate to denosumab) did not influence the outcome variables negatively.